This White Paper, by IQVIA™ Pharma Deals, provides an insightful overview of deal activity in the immuno-oncology market since 2013.
The Immuno-Oncology Market
This emergence of immuno-oncology therapies, which modify the activity of a patient’s immune system with the aim of eliminating cancer cells, has prompted a paradigm shift in the treatment of many cancer types, with approved products spanning a range of mechanisms offering significant efficacy and durable response in certain patient populations across multiple solid and blood-based tumours. The goal of treatment with immuno-oncology therapeutics is to address the unmet need to provide long-term survival in patients with advanced cancers with low toxicity.
Following the launch of the first immune checkpoint inhibitor Yervoy® (ipilimumab) by Bristol-Myers Squibb (BMS) in 2011, the growth of the immuno-oncology market has predominantly been driven by checkpoint inhibitors with PD-1 (programmed cell death-1) and PD-L1 (protein death ligand-1) mechanisms of action that have broad efficacy across a number of solid tumours. Late 2014 saw the market introductions of BMS/Ono Pharmaceutical’s Opdivo® (nivolumab) and Merck & Co.’s Keytruda® (pembrolizumab), two highly anticipated PD-1 targeted agents that have seen rapid uptake owing to their impressive clinical profile. After initial approvals in melanoma and non-small-cell lung cancer (NSCLC), these checkpoint inhibitors are each now approved for use in the treatment of multiple tumour types. For certain indications, eligibility for treatment is based on biomarker status, resulting in improved response rates and outcomes. A number of other cancer immunotherapies have since reached the market, including two CD19-specific autologous chimeric antigen receptor T-cell (CAR-T) therapies that were approved by the US FDA in 2017 following evidence of significant rates of remission in difficult-to-treat tumours